Prostate Cancer
Recent Abstracts
Partial delegation to radiation therapists of the control by onboard imaging of patient positioning - Abstract
February 21, 2013
Rapid and specific electrochemical detection of prostate cancer cells using an aperture sensor array - Abstract
February 21, 2013
High-grade prostate cancer and biochemical recurrence after radical prostatectomy among men using 5α-reductase inhibitors and alpha-blockers - Abstract
February 21, 2013
Targeted prostate biopsies for a histogram of the index lesion - Abstract
February 21, 2013
GU Cancers Symposium 2013 - Real-world experience with sipuleucel-T in metastatic castration-resistant prostate cancer patients ≥ 80 years-old: Data from PROCEED - Session Highlights
February 21, 2013
GU Cancers Symposium 2013 - Immune response to sipuleucel-T in patients with metastatic castrate-resistant prostate cancer (mCRPC): Phase 2 ProACT study, by Thomas A. Gardner, MD, et al. - Session Highlights
February 20, 2013
GU Cancers Symposium 2013 - Aflibercept versus placebo in combination with docetaxel/prednisone for first-line treatment of men with metastatic castration-resistant prostate cancer (mCRPC): Results from the multinational phase III trial (VENICE)
February 20, 2013
GU Cancers Symposium 2013 - A randomized phase II, open-label study of sipuleucel-T with concurrent or sequential abiraterone acetate in metastatic castrate-resistant prostate cancer, by Eric J. Small, MD, et al. - Podcast
February 20, 2013
GU Cancers Symposium 2013 - Trans-Pacific variation in outcomes for men treated with primary androgen deprivation therapy for localized prostate cancer, by Matthew R. Cooperberg, MD, MPH, et al. - Session Highlights and Podcast
February 20, 2013
GU Cancers Symposium 2013 - Open-label, multicenter study of sipuleucel-T in metastatic castrate-resistant prostate cancer patients previously treated with sipuleucel-T: Evaluation of androgen-presenting cell activation, by L. Michael Glode, MD, et al.
February 20, 2013
GU Cancers Symposium 2013 - Utilization of cancer detection by U.S. prostate biospies (2005-2011), by Carl A. Olsson, MD, et al. - Session Highlights and Podcast
February 20, 2013
GU Cancers Symposium 2013 - The ERα agonist, GTx-758, decreases bone turnover markers in men with advanced prostate cancer, by Evan Y. Yu, MD, et al. - Poster
February 20, 2013
GU Cancers Symposium 2013 - Advanced prostate cancer patients treated with GTx-758 have a significantly lower rate of hot flashes, by Evan Y. Yu, MD, et al. - Poster
February 20, 2013
GU Cancers Symposium 2013 - ARN-509 in men with high-risk non-metastatic castration-resistant prostate cancer, by Matthew R. Smith, MD, PhD - Session Highlights
February 19, 2013
GU Cancers Symposium 2013 - ARN-509 in men with high-risk non-metastatic castration-resistant prostate cancer, by Matthew R. Smith, MD, PhD, et al. - Slide Presentation
February 19, 2013
GU Cancers Symposium 2013 - GTx-758, an ERα agonist, reduces serum free testosterone and serum PSA in men with advanced prostate cancer, by Evan Y. Yu, MD, et al. - Poster
February 19, 2013
Elderly prostate cancer patients: Patient information and shared decision making - Abstract
February 19, 2013
Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications - Abstract
February 19, 2013
Combining prostrate-specific antigen and Gleason score increases the diagnostic power of endorectal coil magnetic resonance imaging in prostate cancer pathological stage - Abstract
February 19, 2013
Hybrid registration of prostate and seminal vesicles for image guided radiation therapy - Abstract
February 19, 2013
Page 1162 of 1407
Start
Prev
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
Next
End
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free